May Measurement Month 2019: analysis of blood pressure screening in Bishkek, Kyrgyzstan

Erkin Mirrakhimov 1*, Umid Zakirov 1, Saamay Abilova 1, Azamat Asanbaev 1, Erkaiym Bektasheva 1, Nursultan Asanaliev 1, Yrysbek Mamat uulu 1, Nazira Alibaeva 1, Ksenya Neronova 1, Alina Kerimkulova 1, Olga Lunegova 1, Alina Altymysheva 2, Wei Wang 3, Thomas Beaney 3,4, and Neil R. Poulter 3

1Kyrgyz State Medical Academy named after I.K.Akhunbaev, Akhunbaev Street 92, 720020, Bishkek, Kyrgyzstan; 2WHO Country office in Kyrgyzstan, World Health Organization, Orozbekova Str. 52/54, Bishkek 720040, Kyrgyzstan; 3Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK; and 4Department of Primary Care and Public Health, Imperial College London, St Dunstan’s Road, London W6 8RF, UK

Introduction

Hypertension is one of the leading risk factors for the development of cardiovascular diseases (CVD) and complications. 1–3 According to previous data, the prevalence of hypertension in Kyrgyzstan is between 34 and 45%. 4,5 Based on the high prevalence and low control rate of hypertension in Kyrgyzstan, the Kyrgyz Society of Cardiology decided to join the May Measurement Month (MMM) 6–8 screening campaign in 2019. By participating in the MMM campaign, we hoped to help thousands of people find out their BP levels, raise awareness of high BP and identify other risk factors. In this article, we present the data collected during MMM19 in Bishkek, Kyrgyzstan.

Methods

The MMM campaign is a cross-sectional survey, initiated by the International Society of Hypertension in 2017. Kyrgyzstan joined the campaign in 2019. Study approval was obtained from the local ethics committee. Screening took place in two shopping malls and during the Social
The study included 2013 participants of whom 1006 were women (50.0%) and 1007 men (50.0%). The mean age of the participants was 38.8 (±12.6) years. Of all participants, 940 (46.7%) had their BP measured for the first time. Among all participants, hypertension was detected in 184 participants (9.1%) after imputation. Of the 184 participants with detected hypertension, 59 (32.0%) were aware of their diagnosis. Of the 184 participants with hypertension, 46 (25.0%) received antihypertensive therapy. Of those who received antihypertensive drugs, 32 (69.5%) were on single pill therapy, and 14 (30.5%) were on therapy with two or more pills. Of the 46 participants taking antihypertensive drugs, 25 (54.9%) had controlled BP (<140/90 mmHg) (Table 1).

The mean BMI was 24.0 (±4.1) kg/m²; 534 (26.5%) were overweight, and 202 (10%) were obese. Based on the results of linear regression, both systolic and diastolic BPs were significantly higher among people who were overweight or obese and significantly lower in those who were underweight (Table 2).

Among the 2013 study participants, 34 (1.7%) reported the presence of diabetes mellitus, 12 (0.6%) suffered from previous myocardial infarction, 4 (0.2%) had a stroke, and 314 (15.6%) were current smokers. Forty-one participants (2.0%) drank alcohol one to three times per month, and 46 (2.3%) once or more per week. Screenees who currently smoked had on average a 2.0 mmHg higher mean systolic BP. For participants who drank alcohol one to three times per month had higher diastolic BP compared with non-drinkers (3.9 mmHg, *P* = 0.02). Among women screened, 21 (2.1%) were pregnant at the time of the study and unusually were found to have a 8.3 mmHg higher mean systolic BP than women who were not pregnant after adjusting for age and medication use. Thirty-eight (3.8%) women reported a history of hypertension during previous pregnancy but had no significant difference in their BPs compared to those without hypertension in a previous pregnancy.

### Table 1  Total participants and proportions with arterial hypertension, awareness, on medication and with controlled blood pressure

| Total participants | Number with hypertension | Proportion of all participants with hypertension (%) | Proportion of hypertensives aware (%) | Proportion of hypertensives on medication (%) | Proportion of those on medication with controlled BP (%) | Proportion of all hypertensives controlled (%) |
|--------------------|--------------------------|---------------------------------------------------|----------------------------------------|---------------------------------------------|--------------------------------------------------------|-----------------------------------------------|
| 2013               | 184                      | 9.1                                               | 32.0                                   | 25.0                                        | 54.9                                                    | 13.7                                          |

### Table 2  Relationship of different weight groups with changes in blood pressure

| Systolic/diastolic BMI category | Change in BP compared to baseline (mmHg) | Standard error | *P* Value | 95% confidence interval Lower | 95% confidence interval Upper |
|---------------------------------|------------------------------------------|----------------|------------|-----------------------------|-------------------------------|
| Systolic Underweight            | -4.58                                    | 1.48           | 0.002      | -7.49                       | -1.68                         |
| Systolic Healthy weight (reference) | reference                                    | -              | -          | -                           | -                             |
| Systolic Overweight             | 2.66                                     | 0.76           | <0.001     | 1.16                        | 4.16                          |
| Systolic Obese                  | 6.29                                     | 1.13           | <0.001     | 4.07                        | 8.51                          |
| Diastolic Underweight           | -2.78                                    | 1.03           | 0.007      | -4.79                       | -0.76                         |
| Diastolic Healthy weight (reference) | reference                                    | -              | -          | -                           | -                             |
| Diastolic Overweight            | 2.41                                     | 0.55           | <0.001     | 1.34                        | 3.48                          |
| Diastolic Obese                 | 4.07                                     | 0.80           | <0.001     | 2.50                        | 5.64                          |

*Variables adjusted for age and sex (with an interaction) and antihypertensive medication*

Underweight: <18.5 kg/m²; Healthy weight: 18.5–24.9 kg/m²; Overweight: 25.0–29.9 kg/m²; Obese: ≥30.0 kg/m²
The mean of the first and second BP readings (115.2/75.0 mmHg) was higher than the mean of the second and third BP readings (114.3/74.4 mmHg) among participants with all three BP measurements.

Discussion

In 2019, Kyrgyzstan took part in the MMM campaign for the first time. The study showed that of the 2013 participants screened, the proportion of participants with hypertension was 9.1%, the proportion of people who were aware of their diagnosis was 32.0%, and the proportion of all hypertensives who were controlled was 13.7%. At least half of the participants had not measured their BP in the past 12 months. This study showed low hypertension awareness among residents of Bishkek. This indicates the necessity to increase the awareness of the population of Kyrgyzstan about this disease. In comparison with previous studies, conducted in Kyrgyzstan.4,5 MMM in 2019 showed a higher rate of hypertension control (54.9%) among those treated and a lower prevalence of hypertension. However, this may be because the study was performed only in the city of Bishkek, where the level of healthcare is higher than in other regions of Kyrgyzstan. It may also be related to the places where the research was carried out, mainly shopping centers. Such places are mostly visited by young people. To get a more complete picture of the true prevalence of hypertension in Kyrgyzstan, it is necessary to involve random sampling of all regions of the country.

Acknowledgements

The authors of this publication would like to express their gratitude to all the people who contributed to this study: doctors, residents, managers, and staff at Dordoi Plaza and Asia Mall.

Funding

Study in Kyrgyzstan was supported by Kyrgyz Society of Cardiology.

Conflict of interest: None declared.

Data availability

All data are confidential and may only be provided with permission of authorities.

References

1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Jankowska EA, Michal M, Sacco S, Sattar N, Tekgozoglu L, Tonstad S, Tsioulfas KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227–3337.

2. Jeemon P, Séverin T, Amodeo C, Balabanova D, Campbell NRC, Gaita D, Kario K, Khan T, Melifonwu R, Moran A, Ogola E, Ordunez P, Piret P, Pilsio D, Pinto FJ, Schutte AE, Schutte AE, Wainford R, Poulter NR, Prabhakaran D. World heart federation roadmap for hypertension - a 2021 update. Glob Heart 2021; 16:63.

3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. NCD Risk Factor Collaboration (NCD-RisC). Lancet 2021; 398:957-980.

4. A TA, Makhmutkhodzhaev SA, Khyzhulaeva RB, Altymyshcheva AT, Dzhakipova RS, Zhorupbekova KS, Rysbulatova ST, Niyazova VG, Kaliev MT, Dzhumagulova AS. Prevalence of risk factors of non-communicable disease in Kyrgyzstan: assessment using WHO STEPS approach. Kardiologiia 2016; 56:86–90.

5. Polupanov AG, Khalmatov A, Altymyshcheva A, Lunevova OS, Mirrakhimov AE, Sabirov IS, Kontsevaya A, Dzhumagulova A, Mirrakhimov E. The prevalence of major cardiovascular risk factors in a rural population of the Chui region of Kyrgyzstan: the results of an epidemiological study. Anatol J Cardiol 2020; 24:183-191.

6. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, Cro S, Díaz A, Damasceno A, Espeche W, Jose AP, Khan N, Kokubo Y, Maheshwari A, Marin MJ, More A, Neupane D, Nilsson P, Patil M, Prabhakaran D, Ramirez A, Rodriguez P, Schlaich M, Stockelings UM, Tomaszewski M, Unger T, Wainford R, Wang J, Williams B, Poulter NR. May Measurement Month 2019. Hypertension 2020; 76:333–341.

7. Poulter NR, Lackland DT. May Measurement Month: a global blood pressure screening Campaign. Lancet 2017; 389:1678–1680.

8. Poulter NR, Schutte AE, Tomaszewski M, Lackland D. May Measurement Month: a new joint global initiative by the International Society of Hypertension and the World Hypertension League to raise awareness of raised blood pressure. J Hypertension 2017; 35:1126–1128.